CANDY-CRASH: Impact of Opioids on Heart Rate During Rapid Sequence Intubation
Study Details
Study Description
Brief Summary
The patient is seen upstream by an anaesthetists resuscitator (MAR) in order to carry out his anesthesia consultation. If the patient meets the eligibility criteria he will be informed of the study and his signed consent will be obtained.
Patients will be divided into 3 parallel groups :
-
Group A (placebo +remifentanil)
-
Group B (sufentanil + placebo)
-
Group C (placebo + placebo)
Constants are taken at T0. A non-invasive continuous monitoring (Clearsight ©) will be used to collect data: blood pressure, heart rate, cardiac output.
To ensure double-blinding the nurse who prepares the syringes is not part of the anesthesia team. He/she numbers them in syringe n°1 and n°2 to indicate the order of injection to the MAR.
The MAR injects the drugs according to the standardized study plan (see below):
-
T1: the patient receives an intravenous bolus (IV) over 5 seconds of molecule n°1
-
3 minute delay
-
Patient receives Etomidate 0.3 mg/kg IV over 10 seconds
-
5 second delay
-
The patient receives an IV bolus over 30 seconds of molecule n°2
-
5 second delay
-
The patient receives Succinylcholine or Rocuronium IV over 5 seconds
-
T2: End of induction, oro-tracheal intubation (= T2)
The laryngoscopy is performed by an experienced MAR or nurse (IADE). The end of the intubation is defined by the fixation of the intubation tube (T3). Hemodynamic parameters are measured every minute for ten minutes after intubation (T4 to T13).
Maintenance of anesthesia is standardized with halogen gas (SEVOFLURANE) and an opioid (SUFENTANIL). Ten minutes after the patient's intubation (T13), the blind is lifted, allowing the addition of sufentanil in groups A and C before any surgical procedure.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Group A (placebo + remifentanil)
|
Drug: Remifentanil
REMIFENTANIL, 5 µg/cc, solution for injection, 0.5 µg/kg, parenteral (intravenous) route, injection delay of 30 seconds, once only
Drug: Placebo
PLACEBO contains 0.9% NaCl, parenteral (intravenous), bolus, one-time
|
| Experimental: Group B (sufentanil + placebo)
|
Drug: Sufentanil
SUFENTANIL, 5 µg/cc, solution for injection, 0.2 µg/kg, parenteral (intravenous) route, bolus over 5 seconds, once
Drug: Placebo
PLACEBO contains 0.9% NaCl, parenteral (intravenous), bolus, one-time
|
| Placebo Comparator: Group C (placebo + placebo)
|
Drug: Placebo
PLACEBO contains 0.9% NaCl, parenteral (intravenous), bolus, one-time
|
Outcome Measures
Primary Outcome Measures
- heart rate beats per minute [T2 : oro-tracheal induction]
Absolute variation of heart rate beats per minute between T0 (reference value at the entrance into the operating room) and T2 (end of induction and oro-tracheal intubation)
Secondary Outcome Measures
- Cormack score [T2 : oro-tracheal induction]
Cormack score in each group
- Laryngoscopy number [T2 : oro-tracheal induction]
Laryngoscopy number for each group
- Use of a long bent mandrel [T2 : oro-tracheal induction]
Use of a long bent mandrel for each group
- assess side effects according to the opioids used [T2 : oro-tracheal induction]
Percentage of patients with intraoperative vomiting at T2 for each group
- assess side effects according to the opioids used [before T2 : oro-tracheal induction]
Percentage of patients requiring vasopressor before T2
- assess side effects according to the opioids used [T2 : oro-tracheal induction]
Percentage of patients with thoracic rigidity and/or bradycardia < 50/min at T2 for each group
- assess significant variation in hemodynamic responses [T2 : oro-tracheal induction]
Absolute and relative variations of +-20% in SAP/DAP and MAP between T0 and T2
- assess significant variation in hemodynamic responses [T13 (10 minutes after intubation)]
Absolute and relative variations of +/- 20% in SAP/DA and MAP between T0 and T13
- assess significant variation in hemodynamic responses [T2 : oro-tracheal induction]
Relative variation of +/- 20% of HR between T0 and T2
- assess significant variation in hemodynamic responses [T13 (10 minutes after intubation)]
Absolute and relative variations of +/- 20% of HR between T0 and T13.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient over 65 years old and any possible ASA OR Patient aged 55 to 65 years old with an ASA ≥ 3,
-
Patient undergoing surgery (urgent or scheduled), requiring general anesthesia in rapid sequence, because considered to have a "full stomach", i.e. with: gastro-oesophageal pathology or gastroparesis or a history of bariatric surgery or food intake within two hours for liquids and within six hours for solids,
-
Patient informed of the study who gave their written consent before starting the study procedures,
-
Patient affiliated to a French social security system.
Exclusion Criteria:
-
Patient < 55 years old,
-
Patient on beta blockers,
-
Atrial fibrillation or other rhythm or conduction disturbances,
-
Patient in hemodynamic failure and/or on catecholamines before the start of GA,
-
Patient with intracerebral circulation disorders
-
Combination with opioid agonists-antagonists or partial opioid antagonists
-
Known hypersensitivity to one of the study drugs or to opioids,
-
History of difficult intubation,
-
Patient under guardianship, curatorship or deprived of liberty,
-
Patient participating in another interventional clinical research,
-
Patient under AME (State Medical Aid)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Centre Hospitalier Sud Francilien | Corbeil-essonnes Cedex | France | 91106 |
Sponsors and Collaborators
- Centre Hospitalier Sud Francilien
Investigators
- Principal Investigator: Maeine FONTAINE, MD, Centre Hospitalier Sud Francilien
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EUCT 2022-500369-28-00